JP2020533412A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533412A5
JP2020533412A5 JP2020536496A JP2020536496A JP2020533412A5 JP 2020533412 A5 JP2020533412 A5 JP 2020533412A5 JP 2020536496 A JP2020536496 A JP 2020536496A JP 2020536496 A JP2020536496 A JP 2020536496A JP 2020533412 A5 JP2020533412 A5 JP 2020533412A5
Authority
JP
Japan
Prior art keywords
polymorph according
compound
polymorph
approximately
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020536496A
Other languages
English (en)
Japanese (ja)
Other versions
JP7843116B2 (ja
JP2020533412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049829 external-priority patent/WO2019051147A1/en
Publication of JP2020533412A publication Critical patent/JP2020533412A/ja
Publication of JP2020533412A5 publication Critical patent/JP2020533412A5/ja
Priority to JP2023107781A priority Critical patent/JP2023157909A/ja
Priority to JP2025091579A priority patent/JP2025131661A/ja
Application granted granted Critical
Publication of JP7843116B2 publication Critical patent/JP7843116B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020536496A 2017-09-07 2018-09-07 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 Active JP7843116B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023107781A JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025091579A JP2025131661A (ja) 2017-09-07 2025-06-02 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
US62/555,390 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023107781A Division JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Publications (3)

Publication Number Publication Date
JP2020533412A JP2020533412A (ja) 2020-11-19
JP2020533412A5 true JP2020533412A5 (enExample) 2021-09-30
JP7843116B2 JP7843116B2 (ja) 2026-04-09

Family

ID=65517772

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020536496A Active JP7843116B2 (ja) 2017-09-07 2018-09-07 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2023107781A Pending JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025091579A Withdrawn JP2025131661A (ja) 2017-09-07 2025-06-02 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023107781A Pending JP2023157909A (ja) 2017-09-07 2023-06-30 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025091579A Withdrawn JP2025131661A (ja) 2017-09-07 2025-06-02 ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態

Country Status (24)

Country Link
US (4) US10669236B2 (enExample)
EP (2) EP4674486A3 (enExample)
JP (3) JP7843116B2 (enExample)
KR (2) KR102691700B1 (enExample)
CN (2) CN111278808B (enExample)
AU (2) AU2018330163B2 (enExample)
BR (1) BR112020004419A2 (enExample)
CA (1) CA3074831A1 (enExample)
DK (1) DK3679016T3 (enExample)
ES (1) ES3056703T3 (enExample)
FI (1) FI3679016T3 (enExample)
HR (1) HRP20260002T1 (enExample)
IL (2) IL326637A (enExample)
LT (1) LT3679016T (enExample)
MX (2) MX2020002622A (enExample)
PL (1) PL3679016T3 (enExample)
PT (1) PT3679016T (enExample)
RS (1) RS67706B1 (enExample)
SG (1) SG11202001868RA (enExample)
SI (1) SI3679016T1 (enExample)
SM (1) SMT202500467T1 (enExample)
TW (1) TWI815820B (enExample)
WO (1) WO2019051147A1 (enExample)
ZA (1) ZA202106139B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE602006019822D1 (de) * 2005-09-13 2011-03-10 Sicor Inc Reines rocuroniumbromid
ES2500165T3 (es) * 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
KR20090064400A (ko) * 2006-09-28 2009-06-18 머크 앤드 캄파니 인코포레이티드 Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
SI3592355T1 (sl) 2017-03-10 2026-04-30 Atnx Spv, Llc KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze

Similar Documents

Publication Publication Date Title
TW200901978A (en) Amino-5-[4-(difluoromethoxy)phenyl]-5-phenyl-imidazolone compounds for the inhibition of β-secretase
JP2021504310A5 (enExample)
RU2020121150A (ru) Твердые формы ингибитора калликреина плазмы и его солей
JP2019524883A5 (enExample)
TWI880702B (zh) 作為nrf2活化劑之羥基吡啶并氧氮呯
BR112020007826A2 (pt) derivado de 4-benzopiranona, composição farmacêutica, composição alimentar funcional, método para tratamento de doenças relacionadas ao tnf, composição de reagente, método para inibir uma atividade de tnf
WO1998054159A1 (de) Nichtsteroidale (hetero)zyklisch-substituierte acylanilide mit gemischter gestagener und androgener wirksamkeit
CN108290824B (zh) 索拉贝隆两性离子及其应用
RU2016123382A (ru) Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
WO2017167180A1 (zh) 沃替西汀的帕莫酸盐及其晶型
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
TW201900639A (zh) 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
CN118541358A (zh) 3-[(苯并[d][1,3]二氧戊环-4-基)氧基]丙胺盐酸盐及其光学异构体、晶体及制备方法
MX2007002732A (es) Ligandos de difenil eter terapeuticos.
RU2017131522A (ru) (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
FI3679016T3 (fi) 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja
JP2008503470A (ja) ゴナドトロピン放出ホルモン受容体アンタゴニストの製造法
CN114773349A (zh) 三唑并吡嗪衍生物的新多形体及其制造方法
WO2016059548A1 (en) Processes for the preparation of dabrafenib
JP2020517731A5 (enExample)
CN111801323A (zh) 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物
RU2018135072A (ru) Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения
WO2005079845A1 (ja) 片頭痛予防薬
JP2016094368A (ja) ベンズイミダゾール化合物の新規結晶、及びその製造方法